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1. Introduction 
Bone tissue represents a specialized connective tissue, comprising metabolically active cells 
within a mineralized extracellular matrix, that are vital to the performance of its structural, 
mechanical and metabolic roles (Milat & Ng, 2009). The first descriptions of the bone formation 
process date back to two centuries ago and since then much effort has been spent by the 
scientific community to depict the complete scenario of the cellular and molecular events 
leading to ossification (Howship, 1815; Zaidi et al., 2007). Bone is formed through a complex 
process named osteogenesis, involving the proliferation of mesenchymal precursors, 
condensation of cells in closely interacting groups, differentiation and functional activation of 
bone cells, which finally leads to the deposition of an organic matrix and subsequent 
mineralization. Most bones are formed through the progressive growing and differentiation of 
condensed groups of mesenchymal cells into round chondrocytes that proliferate and secrete 
extracellular matrix (ECM): a cartilage mold is being formed. Thereafter, these cells stop 
proliferating, enlarge, modifiy the ECM composition by changing the type of collagen they 
secrete, and finally direct the mineralization of the new formed tissue. These hyperthrophic 
chondrocytes (HC) signal to adjacent perichondrial cells to stimulate their osteogenic 
differentiation and to promote vascular invasion. In this way, the primitive bone tissue, the 
primary “spongiosa”, is formed starting from the center of the cartilage mold and proceeding 
to surrounding cells, following a longitudinal direction in long bones. Subsequently, 
osteoclasts derived from hematopoietic precursors of the bone marrow enter the cartilage 
mold and digest the ECM synthesized by the HC. These shortly undergo apoptosis at the 
border between cartilage and primary spongiosa, while HC at the extremities of the mold 
continue proliferating. Through the progressive proliferation and hypertrophy of growing 
numbers of chondrocytes, secondary sites of ossification are formed, and the process persist to 
engine the bone lengthening during post-natal life. Flat bones of the skull, conversely, undergo 
a direct “intramembranous” ossification process, as in this case mesenchymal cells directly 
differentiate into osteoblasts that start producing bone matrix. 
The whole process requires a careful coordination of signals within cells, to drive 
proliferation, migration and differentiation in a chronologically and spatially organized 
fashion. It is therefore not so surprising that a wide number of molecules and cross-talking 
pathways drive this coordinated mechanisms through a complex network of interactions 
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which is at least partially known. The best known signaling pathways that orchestrate the 
osteogenic process involve molecules belonging to the wingless-int (WNT), the bone 
morphogenetic protein  (BMP), the hedgehog (HH) and the fibroblast growth factor (FGF) 
families. During the last decades, new details on the control of bone mass remodeling and 
regeneration has been achieved, mainly thank to the rapidly growing body of knowledge 
regarding the genome structure, control and functioning. This chapter will provide an up-
to-date depiction of the molecular networks involved in the osteogenic process, focusing on 
main genes and signaling pathways (schematically represented in Figure 1), whose integrity 
is required for the correct skeletal morphogenesis and patterning and for maintaining bone 
homeostasis. Particular attention will be devoted to list and dissect the human syndromes 
and disorders associated to genes belonging to the main osteogenic pathways, with regard 
to the skeletal phenotype. 
 
 
Fig. 1. The osteogenic network. The figure stigmatizes the main signaling pathways and 
reciprocal cross-talks acting during osteoblast differentiation. See text for details. 
2. Osteogenic genes and pathways 
2.1 The Transforming Growth Factor- ß (TGF-ß) superfamily 
The Transforming Growth Factor- β (TGF-β) superfamily incorporate over 30 
multifunctional growth factors implicated in the regulation of a wide variety of biological 
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functions, such as proliferation, differentiation, migration, and apoptosis. The role of TGF-β 
ligands is context-dependent, being affected by diverse environmental features, including 
tissue and cell type, cell differentiation stage and level of expression of interacting genes. 
Also, the quantity and the quality, in terms of type of isoform, of the growth factor itself, 
along with its paracrine or autocrine effect, influence the downstream cascade. TGF-β 
superfamily members are grouped into 3 families, on the basis of sequence homologies and 
functional activities exploited through the activation of a specific signaling pathway: 1. the 
TGF-β/activin/nodal family; 2. the bone morphogenetic protein (BMP); 3. the growth 
differentiation factor (GDF)/Muellerian inhibiting substance (MIS) family. As a rule, all the 
molecules acting in the TGF-β signaling pathway are extremely conserved across species 
during evolution (Miyazono, 2000).  
A fine regulation of the spatio-temporal expression and function of TGF-β pathway players 
occurs during embryonic development, leading to an astounding heterogeneity of cellular 
responses (Ripamonti et al, 2006). Signaling is initiated when binding of the ligand induces 
the assembly of a heteromeric complex of type I and type II serine/threonine kinase 
receptors (Cohen, 2006; Miyazono, 2000). The constitutively active type II receptor recruits 
and activates a type I receptor (also known as activin receptor-like kinase; ALK) by 
phosphorylating its cytoplasmic domain, inducing the assembly of two type I, and two type 
II receptors. This, in turn, results in the phosphorylation and activation of specific 
intracellular proteins, belonging to the SMAD (mothers against decapentaplegic (MAD) 
homologs) family, by the type I receptor (receptor-regulated Smads, R-Smads: Smad1–3, 5, 
and 8). The consequent activation of the Smad signaling cascade implies the formation of 
heterodimeric complexes with the common partner Smad (Co-Smad, Smad4), which 
translocates to the nucleus and recruits distinct transcription factors to regulate 
transcription. The transcriptional targets of this signaling pathway are represented by over 
500 genes, which are regulated in a cell-specific, ligand dose–dependent manner (Cohen, 
2006; Miyazono, 2000). Generally, Smad-2 and -3 transduce cellular responses downstream 
of the TGF- β and activin receptors, while Smad-1, -5 and -8 primarily mediate BMP signals 
(as further discussed). Signaling by the TGF- β family is carefully regulated at several levels, 
through either of the TGF-β ligand agonists and antagonists, which compete for receptor 
binding, or capture the ligand in the extracellular compartment. In addition, the different 
downstream effects of TGF-β signalling activation are due to the different combinations of 
receptors (seven type I receptors and five type II receptors are classified), leading to 
alternative ligand-specific composition of the receptor complex. Finally, diverse biological 
response to the same signaling pathway are also obtained through the recruitment of 
different accessory proteins (Kanaan RA & Kanaan LA, 2006). The vast majority of TGF-β 
superfamily members actively involved in bone formation belong to the most numerous 
family, represented by the bone morphogenetic proteins. 
2.2 Bone morphogenetic proteins (BMPs) 
Bone morphogenetic proteins (BMPs) were originally identified and named after their 
ability to induce ectopic bone formation (Urist, 1965). The BMP family comprises over 20 
distinct highly conserved secreted proteins, further categorized into multiple subgroups 
according to functional and/or structural features (Miyazono et al., 2005; X. Wu et al., 2007). 
BMP functions cover several aspects of the cell differentiation program. In particular they 
induce the osteoblastic commitment of mesenchymal cells, inhibit their differentiation along 
the myoblastic and adipogenic lineage and increase osteoclastogenesis (Katagiri et al., 1994; 
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Okamoto et al., 2006; Pham et al., 2011; X. Wu et al., 2007). On the whole, BMPs play a 
pivotal role in skeletogenesis during all processes associated with limb development. 
Nonetheless, the biological activities of BMPs are not identical among members. In fact, 
despite their name, not all members of the BMP family are directly involved in 
skeletogenesis; they display distinct spatio-temporal expression patterns, with consequent 
diversified roles in the morphogenesis of even non-skeletal structures during embryo 
development (H. Chen et al., 2004; Cheng et al., 2003; Dudley et al., 1995; Jena et al., 1997; 
Luo et al., 1995; Mcpherron et al., 1999; Solloway et al., 1998; Zhao et al., 1996). 
BMP2, BMP4 and BMP7 (also known as osteogenic protein-1, OP-1, see Figure 1) are the 
most extensively studied osteogenic BMPs, being involved in basic skeletal body patterning 
mechanisms (Bahamonde et al., 2001; Gimble et al., 1995; Ozkainak et al., 1990). In vitro, 
BMP-2, BMP-4, and BMP-7 can induce the differentiation of multipotent mesenchymal cells 
into both osteochondrogenic lineage cells and osteoblast precursor cells, suggesting their 
essential contribute to both direct and indirect ossification mechanisms occurring in 
vertebrates (Balint et al., 2003; Canalis et al., 2003; Yamaguchi et al., 2000). BMP2 and BMP4 
are essential during embryonic development; mice deficient in BMP2 are not viable because 
of amnio-chorial defects and severe impairment of cardiac development. The BMP4-null 
mutation is lethal between 6.5 and 9.5 days of gestation because of the lack of mesodermal 
differentiation and patterning defects (X. Wu et al., 2007). During skeletal development, 
BMP2/4 are involved in the molecular regulation of condensation, the pivotal stage during 
which previously dispersed mesenchymal progenitors proliferate, migrate and aggregate to 
form a growing cell mass (Hall et al., 1995). The molecular basis of BMP osteogenic 
properties have been extensively studied in vitro, studying the osteoblastic differentiation 
process and in vivo using transgenic and knockout mice along with animals and humans 
with naturally occurring mutations in the corresponding genes (D. Chen et al., 2004). 
Disruption of BMP7, leads to multiple skeletal defects, lack of eye and glomerular 
development, and subsequent renal failure and neonatal death (Jena et al., 1997). A wide 
number of preclinical studies have been demonstrating that these small molecules are 
capable of inducing ectopic bone formation upon intramuscular implantation and efficient 
bone healing/regeneration, when delivered in the appropriate concentration and on the 
appropriate scaffold into a bone defect site (Boden, 2005; Evans, 2011; Lattanzi et al., 2005). 
The use of recombinant human BMP2 and BMP7 has been approved both in Europe and the 
United States for selected clinical applications, as an alternative to autogenous bone grafts in 
the axial and appendicular skeleton. However, despite significant evidence of their potential 
benefit to bone repair there is, to date, a dearth of convincing clinical trials (Gautschi et al., 
2007). On this regard, the main limitation of using recombinant proteins for inducing bone 
formation in clinical applications is the need for delivery systems that provide a sustained, 
biologically appropriate concentration of the osteogenic factor at the site of the defect 
(Lattanzi et al., 2008; Parrilla et al., 2010). 
2.2.1 BMP receptors and intracellular signal transduction 
BMP actions are mediated through the interaction with different sets of transmembrane 
serine/threonine kinase receptor complexes, grouped in two types, BMPRI and BMPRII 
(Massague, 1998; Zwijsen et al., 2003). BMP family members bind to their receptors with 
different affinities and in different combinations, determining the specificity of the 
downstream intracellular signals (F. Liu et al., 1995). BMPRI receptors include BMPR-IA 
(ALK-3), BMPR-IB (ALK-6), and ActR-IA (ALK-2) (Wan & Cao, 2005). BMPRII, activin type 
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IIA receptor (ActRIIA), and activin type IIB receptors (ActRIIB) are type II receptors, which 
bind exclusively BMP ligands, including BMP2, BMP4 and BMP7 (Wan & Cao, 2005). 
Generally, the type-I receptors are high-affinity binding receptors, whereas the type II 
receptors bind with lower affinity exclusively ligands belonging to the BMP family (X. Wu 
et al., 2007). BMPR-IB is the only receptor expressed within all types of cartilage and is 
required for correct chondrogenesis and osteogenic differentiation. ALK2 is expressed in 
isolated chick osteoblasts and chondrocytes, and overexpression of constitutively active 
ALK2 enhances chondrocyte maturation, suggesting that it is essential for normal 
endochondral ossification (X. Wu et al., 2007). Both type I and type II receptors are 
expressed on the cell surface; upon BMP2 binding, the type-II receptor transphosphorylates 
the type-I receptor. On its turn, the activated type I receptor phosphorylates of selected 
members of the Smad family of signal transduction proteins, namely Smad1, 5, and 8 
(Kawabata et al., 1998; Nohe et al., 2002). The consequent activation of the Smad signaling 
cascade implies the formation of heterodimeric complexes with the common partner Smad 
(Co-Smad, Smad4), which translocate to the nucleus and recruit distinct transcription factors 
to regulate transcription, as illustrated in the following paragraphs (Wan and Cao, 2005; 
X.Wu et al., 2007). The cascade is sintetically depicted in Figure 1. As an alternative 
mechanism, BMP2 can also bind to preformed heteromeric receptor complexes and activate 
a Smad-independent transduction cascade, which results in the induction of alkaline 
phosphatase activity via p38-mitogen-activated protein kinase (MAPK; Kozawa et al., 2002; 
Guicheux et al., 2003; Nohe et al., 2002). BMP3 (osteogenin) appears to antagonize the 
osteogenic effects of BMP2 in stromal cells, likely acting via an activin-mediated pathway 
(Bahamonde et al., 2001). 
2.2.2 BMP dowstream targets in bone biology 
BMP2 is usually considered a paradigmatic model for studying bone formation 
mechanisms, since the original demonstration of its efficacy in inducing ectopic bone 
formation in muscles (E. A. Wang et al., 1990). In vitro, a wide number of studies 
demonstrated that BMP2 is able to induce the osteogenic differentiation of mesenchymal 
cells and transdifferentiation of myoblast into osteoblasts (reviewed by Ryoo et al., 2006). 
The BMP2 signaling involved in the osteoblast differentiation program, proceed 
downstream of the Smad cascade with the recruitment of osteo-specific transcription factors. 
The best characterized as the master osteogenic transcription factor induced by Bmp2 is the 
Runt-related transcription factor 2 (Runx2), because mice lacking Runx2 show complete 
arrest in osteoblast maturation and consequent absence of bone (Komori et al., 1997). Runx2 
induces the expression of bone marker genes (including alkaline phosphatase, ALP, 
osteocalcin, osteopontin, bone sialoprotein and bone-specific collagens) through binding the 
osteoblast-specific cis-acting element-2 (OSE2), which is found in the promoter region of 
osteoblast-specific genes (Ziros et al., 2002). Runx2 is believed to function during the initial 
steps of osteogenic differentiation, from cell commitment to the chondro-osteogenic switch 
in endochondral ossification (Ryoo et al., 2006). The zinc finger-containing transcription 
factor Osterix (Osx) represents another piece in the mosaic work of Bmp2 action. Osx is 
expressed in developing bones and seems to act in the terminal differentiation of 
osteoblasts. As for Runx2, Osx-deficient mice display total absence of bone (Nakashima et 
al., 2002). Recent studies indicate that Runx2 and Osx mRNAs are not directly up-regulated 
by Bmp2, suggesting the existence of crucial intermediators, possibly represented by 
selected members of the Distal-less homeobox family (Dlx; further described in paragraph 
 
Osteogenesis 
 
26
2.10). Dlx5 is a homeodomain-containing transcription factor that is expressed in later stages 
during osteoblast differentiation and induces the expression of osteocalcin and the 
formation of a mineralized matrix (Ryoo et al., 2006). Dlx5 is believed to play an 
evolutionarily conserved role in skeletogenesis, as Dlx5-deficient mice display severe 
craniofacial abnormalities and delayed cranial ossification (Acampora et al., 1999). Dlx5 
transcription is induced by Bmp2 signaling and could represent an upstream regulator of 
both Runx2 and Osx (Ryoo et al., 2006). 
2.2.3 BMP antagnosists, inhibitors and further interactions 
BMP signaling is modulated at different levels: extracellular BMP antagonists compete for 
receptor binding on the cell surface; inhibitory Smads and interacting molecules can 
interfere with the correct function of the intracellular Smad cascade; furthermore, alternative 
signals from co-existing transduction pathways converge on the same downstream targets 
to cooperate or antagonize BMP function on gene expression and protein processing.  
BMP antagonists have been recently classified into three subfamilies based on the size of a 
cysteine-rich domain, known as cystine-knot, that characterizes many TGFβ superfamily 
members: the “Differential screening-selected gene aberrative in neuroblastoma” (DAN) 
family; the twisted gastrulation; and chordin and noggin. The DAN family is further 
subdivided in into four subgroups based on a conserved arrangement of additional cysteine 
residues outside of the cystine-knots: group 1 includes PRDC (Protein Related to Dan and 
Cerberus) and gremlin; group 2, coco and Cer1, homologue of Xenopus Cerberus; group 3 
comprises the ; finally, group 4, sclerostin and USAG-1. All these molecules are involved in 
embryo development at various levels, representing also crucial node of intersection 
between Wnt- and BMP-signaling (Yanagita, 2005). 
With regard to bone formation, the best studied antagonists of BMP signaling are noggin 
and chordin, which are structurally and fuctionally related, and regulate BMPs availability 
in the extracellular compartment (Rosen, 2006). 
2.2.3.1 Noggin 
Noggin (Nog) is a glycosylated chemokine protein, which is able to form a neutralizing 
complex that prevents BMPs from binding to BMPRs (Groppe et al., 2002; Krause et al., 
2011). Nog action intervene as early as during gastrulation, where it antagonizes BMP-2, -4 
and -7 and generates a dorsal-ventral BMP gradient which is crucial for the germ layer 
formation. Nog effects are pleiotropic during embryo development, although they are 
mainly explicated toward the formation of ectoderm and mesoderm derivatives (Krause et 
al. ,2011). In fact, Nog expression is essential for proper skeletal development, as excess BMP 
activity in Nog-null mice results in excess cartilage and failure to initiate joint formation, 
along with additional severe developmental abnormalities leading to premature embryo 
lethality (Brunet et al., 1998; McMahon et al., 1998; Tylzanowski et al., 2006). Conversely, 
ectopic expression of Nog in developing embryos results in suppression of lateral somite 
differentiation and complete inhibition of chondrogenesis in limbs (Capdevila & Johnson, 
1998). Transgenic mice overexpressing noggin in mature osteoblasts show a dramatic 
decrease in bone mineral density and bone formation rate due to impaired osteoblast 
recruitment and function (X.B. Wu et al.., 2003). Most known Nog functions are based on its 
antagonism against BMP4 signalling, during both endochondral bone formation and teeth 
formation and eruption (Groppe et al., 2002; Tucker et al., 1998). Nog expression is regulated 
through a feedback system, as diverse BMPs (namely BMP2, -4, -5, -6 and -7) induce Nog 
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expression in osteoblasts, while Indian hedgehog (Ihh) induce Nog expression in 
chondroytes (Krause et al., 2011). Finally, Nog expression is down-regulated by fibroblast 
growth factor-2 and -9 (FGF-2 and FGF-9) in the mesenchyme during cranial suture fusion 
in mice. Hence, it is speculated that the biological effects of gain-of-function mutations of the 
FGF receptor genes, typically associated to abnormal skeletal penotypes with cranial and 
limb malformations (see paragraph 2.6.2), are partially due to inappropriate inhibition of 
noggin expression (Warren et al., 2003). 
2.2.3.2 Chordin 
Similarly to noggin, chordin (CHRD) contains the cysteine-knot structure in its 
biochemical structure and is able to bind BMPs and sequester them in latent non-
functional complexes. The formation of the Chrd-BMP complex completely prevents 
binding of Bmp2 to both BMPR1A and BMPR2 receptors, leading to dorsalization of early 
vertebrate embryo (Scott et al., 1999). Chrd binds predominantly to BMP2 and BMP4, 
although it has been demonstrated that BMP1 overexpression counteract the dorsalizing 
effects of chordin, suggesting that also BMP1 should be among the major chordin 
antagonists in early mammalian embryogenesis and in pre- and postnatal skeletogenesis 
(Scott et al., 1999). Furthermore, in mouse, Chrd binds also to Bmp7 with similar affinity 
(Zhang et al., 2007). Chordin is supposed to play a role during the very early embryo 
patterning, as it is expressed in the anterior primitive streak, in the node and subsequent 
axial meso-endoderm. Similarly to Nog, Chrd deficiency is early lethal in mice and is 
associated to a ventralized gastrulation phenotype. Stillborn animals have normal early 
development and neural induction but display later defects in inner and outer ear 
development and abnormalities in pharyngeal and cardiovascular organization (Bachiller 
et al., 2000). The expression and function of Chrd and Nog in the midgastrula strictly 
overlap. It seems that they can compensate for each other during early mouse 
development, as suggested by studying the phenotypic effects of combined Chrd/Nog 
mutations in mice. When both gene products are removed, antero-posterior, dorso-
ventral, and left-right patterning are all affected in mice, with severe disruption of 
mesoderm development (Bachiller et al., 2000). 
2.2.3.3 Sclerostin and USAG-1 
Sclerostin (Sost), recently classified among BMP antagonists, was originally identified as the 
gene responsible for the autosomal recessive progressive sclerosing bone dysplasia, known 
as sclerosteosis (MIM#269500; Brunkow et al., 2001). In scleosteosis, loss of SOST prolongs 
the active bone-forming phase of osteoblasts, resulting in the increased bone mass. Sost is 
abundantly expressed in long bones and cartilages and binds to BMP-6 and -7 with highest 
affinity (Kusu et al., 2003; Winkler et al., 2003). Sost is expressed exclusively by osteocytes, 
and inhibits the differentiation and mineralization of murine preosteoblastic cells (van 
Bezooijen et al., 2004). 
Transgenic mice overexpressing Sost exhibited low bone mass and decreased bone strength 
due to reduced osteoblast activity and bone formation (Winkler et al., 2003). The mechanism 
of action of Sost should be based on the inhibiton of BMP-induced Smad phosphorylation 
and alkaline phoaphatase (ALP) activity, though there are still controversies regarding this 
issue (Yanagita, 2005). It also acts as an inhibitor of the Wnt-signalling pathway, by binding 
and blocking the Wnt receptor LRP-5 (see paragraph 2.3.2). 
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Also another rare skeletal disease characterized by high bone mass, osteopetrosis or van 
Buchem's disease, already associated to LRP5 gene mutations, has been linked to 
inactivating mutations in the SOST gene (see Table 1 and 2). This finding highlighted the 
role of sclerostin in the homoeostasis of bone mass, and provided the rationale to target 
sclerostin with monoclonal antibodies to enhance bone formation. In a rat model of post-
menopausal osteoporosis due to ovariectomy, treatment with a sclerostin antibody 
increased bone mass at all skeletal sites and completely prevented bone loss associated 
with oestrogen deficiency. 
Another cysteine-knot secretory protein recently classified among the BMP antagonists is 
the uterine sensitization-associated gene-1 (USAG-1), originally found in rat endometrium 
upon sensitization, hence its name, and found expressed in the human kidney (Yanagita, 
2005). USAG-1 share 38% identity to SOST aminoacid sequence, so that, also based on their 
functional overlap, the two moelcules could be grouped in a distinct family of BMP 
antagonists. Recombinant USAG-1 protein binds and inhibits BMP-2, -4, -6, and -7 with high 
affinity, reducing ALP activity in mesenchymal cells and pre-osteoblasts. 
2.2.3.4 LIM-mineralization proteins 
Among the BMP-interacting molecules, it is worth to mention the recently discovered Lim 
mineralization protein (LMP), an intracellular LIM-domain protein acting as a potent 
positive regulator of the osteoblast differentiation program (Bernardini et al., 2010). LMP 
was originally identified and cloned from rat calvarial osteoblasts stimulated by 
glucocorticoids, and subsequently emerged as a novel attractive osteogenic molecule able to 
induce the activation of the BMP signaling pathway (Boden et al., 1998; Boden et al., 1998b; 
Viggeswarapu et al., 2001). In humans, three different splice variants are transcribed from 
the LMP-coding gene (PDZ and LIM doamin-7, PDLIM7): LMP1 is the longest transcript, 
encodes the full-length protein isoform comprising conserved PDZ and LIM domains plus a 
non-conserved region, and has demonstrated osteogenic properties; LMP2, misses over 100 
nucleotides within the non-conserved region and does not induce bone formation; finally 
the LMP3 isoform is the result of a more complex post-transcriptional processing that 
produces a smaller peptide missing all LIM domains while retaining a shorter non-
conserved sequence (H.S. Kim et al., 2003; Y. Liu et al., 2002; Viggeswarapu et al., 2001). 
Despite the truncation of nearly two third of the full-length isoform, LMP3 retains efficient 
osteogenic properties, demonstrated in vitro and in different animal models (Lattanzi et al., 
2008; Parrilla et al., 2010; Pola et al., 2004). In vitro, both LMP1 and LMP3 induce osteogenic 
differentiation of mesenchymal progenitors, fibroblasts and pre-osteoblasts, through the 
transcriptional activation of BMP-family members (mainly BMP2, BMP4 and BMP7) and 
TGFβ1 protein (Bernardini et al., 2010 ; Minamide et al., 2003). LMP1 osteogenic properties 
are also based on interactions with the Smad ubiquitin regulatory factor 1 (Smurf1), thus 
preventing Smads ubiquitination and potentiating BMP signaling, along with the insulin-
growth factor biniding protein-6 (IGFBP6), a potent indcutor of osteoblast differnetiation 
(Sangadala et al., 2006; Strohbach et al., 2008). In addition, it suppresses osteoclast activity 
acting through the mitogen-activated protein kinase (MAPK)-signaling, which implies more 
pleiotropic effects to be exerted by the peptide (H. Liu et al., 2010). The effectiveness of 
LMPs in inducing bone formation in vivo has been demonstrated, using different strategy to 
deliver the gene/peptide at the site where the bone healing was required (H.S. Kim et al., 
2003; Lattanzi et al., 2008; Parrilla et al, 2010; Pola et al., 2004; Sangadala et al., 2009; 
Strohbach et al., 2008b; X. Wang et al., 2011; Yoon et al., 2004). So far, the expression of 
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human LMPs has been detected in the iliac crest bone, in teeth and in calvarial tissues and 
cells (Bernardini et al., 2011; Bunger et al., 2003; Fang et al., 2010; X. Wang et al., 2008). 
2.2.4 Skeletal phenotypes associated to BMPs 
At least four molecules that are directly involved in the BMP-TGFβ pathway are mutated in 
human syndromes comprising skeletal malformations in their phenotypes, due to the 
actions carried out during throughout development in mesoderm induction, tooth 
development, limb formation, bone induction, and fracture repair. Table 1 summarizes the 
mendelian disorders allelic to BMP-related gene mutations categorized in the “online 
mendelian inheritance in man” (OMIM) database (www.omim.org). Main differences in 
human phenotypes associated to different genes are evident, reflecting the diversified gene 
functions during skeletal development and patterning. In particular, while heterozygous 
mutations in the BMP4 gene are associated to minor facial malformations, different point 
mutations in the human homolog of the murine Nog (NOG) can cause five different 
phenotypes, invariably carachterized by limb malformations, and other skeletal anomalies 
due to impaired endochondral ossification. This could possibly reflect more pleiotropic roles 
for NOG (see Table 1). 
 
Genea Diseases MIMb 
BMP4 Syndromic microphtalmia 
Orofacial cleft 
607932 
600625 
BMPRIB brachydactyly, type A2 
Acromesomelic chrondrodysplasia with genital anomalies  
112600 
609441 
NOG brachydactyly, type B2 
multiple synostosis syndrome 
stapes ankylosis with broad thumb/toe 
proximal symphalangism 
tarsal-carpal coalition syndrome 
611377 
186500 
184460 
185800 
186570 
SOST Sclerosteosis 269500 
a. gene symbol is provided; b. Mendelian Inheritance in Man (MIM) ID code. 
Table 1. Mendelian diseases associated to BMP family mutations 
2.3 WNT signaling 
Since the original discoveries of the role of Wnt signalling in bone formation and 
skeletogenesis (Hartmann & Tabin, 2001; Lako et al., 1998), there has been a stream of 
research aimed at elucidating the complex roles that Wnt proteins, endogenous Wnt 
inhibitors and interacting molecules play in the regulation of bone mass, revelaing that they 
play a vital role in adult tissue maintenance (Milat & Ng, 2009). 
2.3.1 Wnt proteins 
The “wingless-type mouse mammary tumor virus (MMTV) integration site” family (WNT) 
consists of structurally related genes which encode secreted signaling glycoproteins, which 
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are extremely conserved in evolution. They are implicated in oncogenesis and in several 
developmental processes, including regulation of cell fate, early axis specification, organ 
development and patterning during embryogenesis (Hartmann & Tabin, 2000, 2001). Hence, 
aberrations in Wnt signalling lead to complex developmental diseases.  
WNT family members are defined by sequence homology to the Drosophila wingless (wg) 
and the murine int-1 proto-oncogene, hence the family name. The first Wnt gene was cloned 
30 years ago (Nusse & Varmus, 1982); to date, nineteen Wnt genes have been identified in 
the mouse and human genomes (http://www.stanford.edu/rnusse/wntwindow.htlm; 
Milat & Ng, 2009). Wnt proteins are traditionally categorized into two classes, canonical and 
non-canonical, based on their in vivo and in vitro activities that are exerted through distinct 
molecular signal transduction mechanisms. Canonical Wnts (including Wnt1, Wnt3A, Wnt8, 
Wnt10b) activate a cascade that results in the translocation of β-catenin (cadherin-associated 
protein, beta 1, CTNNB1) to the nucleus, where it associates to the lymphoid-enhancer 
binding factor/T-cell specific transcription factors (TCF/LEF) that finally induces the 
expression of target genes (Logan et al., 2004; Milat & Ng, 2009). The canonical pathway, the 
best studied, initiate when a canonical Wnt-ligand binds to one of the Frizzled (Fz) 
receptors. This event inactivates the glycogen synthase kinase 3 (GSK3), through the 
developmental transducer phosphoprotein Dishevelled (Dvl), and therefore prevents 
phosphorylation and consecutive proteosomal-degradation of β-catenin (Westendorf et al., 
2004; Behrens et al., 1996). 
Non-canonical Wnts (including Wnt4, Wnt5a and Wnt11) activate transcription through 
β-catenin-independent signaling pathways, involving alternative intracellular second 
messengers. At least three alternative non-canonical Wnt pathways could be described. 
One is based on the intracellular release of Ca2+ that activates calcium-sensitive enzymes, 
which on their turn activate specific transcription factors (A.E. Chen et al., 2005). This 
Wnt-cGMP/Ca2+-protein kinase C dependent pathway plays important roles during 
dorso-ventral patterning of the embryo, regulating cell migration, as well as heart 
development, and might play a role during tumor suppression (Piters et al., 2008). The 
planar cell polarity (PCP) signaling (Mlodzik, 2002) represent another non-canonical Wnt-
pathway, required for embryonic morphogenesis, activated through Fz receptors binding 
and results in the coactivation of Rho and Rac, two small GTPases that are able to regulate 
cytoskeletal architecture (Piters et al., 2008). Finally, the Wnt-protein kinase A (PKA) 
pathway is based on the increase cAMP levels, which activates PKA and the transcription 
factor CREB and has been implicated in myogenesis in mice (Kuhl et al., 2000; Semenov et 
al., 2007). 
Recent evidences suggested that the distinct signaling pathways are alternatively activated 
through the binding of distinct sets of receptors, regardless of the original classification of 
canonical versus non-canonical Wnts (van Amerongen et al., 2008). 
2.3.2 Wnt receptors 
The mechanism by which Wnt binding to its receptors triggers the downstream signalling 
has been extensively studied, although a conclusive and comprehensive view has not been 
achieved so far (Fuerer et al., 2008). The best known Wnt receptors belong to the Frizzled 
(Fzd) family, which includes ten G protein-coupled transmembrane receptors (FZD1-to-10; 
Wodarz & Nusse, 1998). Thereafter, various members of the density lipoprotein receptor 
(LRP) family (LRP5 and LRP6) have been shown to be essential co-receptor for Wnt 
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signalling (Tamai et al., 2000; Wehrli et al., 2000). LRP phosphorylation by activated Wnt is 
critical and requires the cooperative roles of FZD, the cytoplasmic scaffolding proteins 
dishevelled (Dsh/Dvl) and axin, and GSK3, within the canonical pathway (Bilic et al.., 2007; 
Davidson et al., 2005). 
2.3.3 Wnt targets 
A large number of Wnt target genes have been identified to date, in over twenty studies 
based on genome-wide approaches (e.g. microarray-based gene expression profiling) in 
different cell lines and tissues (http://www.stanford.edu/rnusse/pathways/targets.html). 
Distinct in vitro studies provided the evidence of “feedback targets” of Wnt, that are Wnt 
signalling components whose expression can be regulated by the signaling itself, indicating 
that feedback control is a key feature of Wnt signaling regulation. In particular, over 150 
genes have been identified as direct transcriptional targets of the Wnt canonical pathways, 
as they contain Tcf/Lef binding sites, including basic regulators of cell 
proliferation/tumorigenesis (c-myc, cyclin D, c-jun, among others), growth factors (FGF9, 
FGF20, VEGF, BMP4), transcription factors (RunX2), and a wide number of genes implicated 
in cell adhesion and differentiation (see the gene-lists available at the web site above 
indicated). 
2.3.4 Wnt in bone biology 
An extensive review of the scientifc literature reveals that Wnt proteins play a leading role 
in bone development and homeostasis. In this respect, the canonical Wnt pathway has been 
most extensively studied for its role in skeletogenesis, 
There is in vitro evidence that Wnt proteins are produced by calvaria, primary osteoblasts 
(Wnt1, Wnt4, Wnt14) and osteosarcoma cell lines. Wnt genes (e.g. Wnt7b) are up-regulated 
during osteogenic differentiation of bone marrow stromal cells (Kato et al., 2002; Gregory et 
al, 2005). Some Wnt proteins (Wnt10b, Wnt1,Wnt2 and Wnt3a) have an effect on bone 
physiology, as they regulate bone marker gene expression (osteocalcin, RunX2, Osterix, 
alkaline phosphatase), stimulate osteoblastogenesis and inhibit adipogenesis, mainly 
through the canonical pathway (Takada et al, 2009). Mice lacking either Wnt10b or Wnt5a 
display impaired bone structure organization and reduced bone mass due to hypoplasia 
(Bennet et al., 2005; Takada et al., 2007). Wnt5a seems to act through CaMKII rather than 
TCF/LEF, thus suggesting that both the canonical and non-canonical Wnt signalling 
pathways play a role in osteoblastogenesis (Milat & Ng, 2009). Mice lacking Lrp5 display a 
low bone mass secondary to reduced osteoblast proliferation (Kato et al., 2002). Similarly in 
humans, a loss-of-function mutation in LRP5 occurs in the osteoporosis-pseudoglioma 
syndrome (OPPG, MIM#259770; Table 2), an autosomal recessive syndrome characterized 
low bone mass, ocular defects, and predisposition to fractures (Gong et al., 2001). 
Conversely, the gain-of-function mutation in Lrp5 may not have an effect on bone density 
when expressed in mature osteoblasts and can be associated to increased bone mass, due to 
inhibition of Wnt sigaling (Yadav et al., 2008). 
Moreover, LRP5 inhibits tryptophan hydroxylase (Tph1) expression, a rate-limiting 
enzyme in the gut-derived serotonin biosynthetic pathway, impairing serotonin synthesis. 
Serotonin on its turn regulates the bone mass (Warden et al., 2005), in fact, gut-specific 
deletion of LRP5 results in low bone mass, similarly to the phenotype observed in LRP5-
null mice (Yadav et al., 2008). Reasonably, this could provide the first possible explanation 
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of the complex gut–bone interactions in the regulation of bone mass (Milat & Ng, 2009). 
Conversely, osteoblast-specific deletions of LRP5 do not cause osteoblast defects. LRP5 
may be involved in postatal regulation of osteoblast differentiation and it is possible that 
LRP6, rather than LRP5, is the critical co-receptor for Wnt signalling in bone. As a proof of 
evidence, LRP6 loss of function bone phenotype is much more severe than that associated 
to LRP5 loss. The LRP6−/− genotype is lethal in mice, while heterozygous mice display 
reduced bone mass (Pinson et al., 2000). In humans, a missense mutation in LRP6, with 
consequent impairment of Wnt signalling, has been associated to an autosomal dominant 
early coronary artery disease, to metabolic risk factors and to osteoporosis (Mani et al.., 
2007). 
β-catenin (CTNNB1) mutations appeared to affect bone resorption by regulating, in 
differentiated osteoblasts, the expression of osteoprotegerin (OPG), which controls 
osteoclast differentiation (Glass et al., 2005; see paragraph 2.8). Also, conditional deletion of 
Ctnnb1 in mouse embryo limb and head mesenchyme resulted in blockage of osteoblastic 
differentiation of mesenchymal precursors (Day et al., 2005; Hill et al.,2005). Ctnnb1 is 
indeed crucial in determining the correct osteoblastic fate of mesenchymal progenitors in 
the developing embryo (Hill et al., 2005). 
Wnt signaling is also involved in the transcriptional modulation of the molecular events 
leading to cartilage differentiation. Ectopic canonical Wnt signaling leads to enhanced 
ossification and suppression of chondrocyte formation during skeletogenesis (Day et al., 
2005). On the other hand, during both intramembranous and endochondral ossification, b-
catenin inactivation induces ectopic chondrocyte formation in place of osteoblast 
differentiation. Moreover, Wnt signaling is essential for skeletal lineage differentiation, 
preventing transdifferentiation of osteoblasts into chondrocytes, and control stem cell self 
renewal, proliferation and fate lineage specification, by regulating the balance between FGF 
and BMP signaling (Hill et al., 2005). 
2.3.5 Wnt-signaling inhibitors 
Other ligands can bind the Fzd–LRP5/6 receptor complex, thus antagonizing Wnt signal 
transduction pathway. Dickkopfs (Dkk) proteins, compete for the LRP5/6 receptor and 
prevent canonical signalling. Dkk are involved in epithelial-mesenchymal transition during 
mesodermal tissue development and play an important role in bone biology. DKKs role in 
vertebrate development is due to their local inhibitory funtion on Wnt-regulated processes, 
such as antero-posterior axial patterning, limb development, somitogenesis and eye 
formation (Pinzone et al, 2009). 
Dkk1 binds to LRP6 with high affinity and is expressed by osteocytes and osteosarcoma 
cells. When overexpressed, DKK1 induce osteopenia, while Dkk1 loss induces increased 
bone formation in mice (Milat & Ng 2009). In humans, an increase of DKK1 expression in 
leukocytes was associated to the presence of bone lesions in myeloma patients (Milat & Ng, 
2009). The role in bone homestasis of other Wnt inhibitors, such as the secreted frizzled 
related protein-1 (sFRP1) and the Wnt inhibitory factor 1, (WIF-1) has been explored and 
demonstrated so far exclusively in animal and cellular models (Milat & Ng, 2009). 
It is worth to mention that close relationships between the BMP- and the WNT-signaling 
occur at this level; Dkk1 and Nog cooperate in mammalian head induction (del Barco 
Barrantes et al., 2003); the expression of DKK1 is regulated by BMP-4 in limb development 
(Grotewold et al., 2002). Furthermore, the mutlifunctional antagonist called Cerberus, a 
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potent inducer of head formation during vertebrate development, has distinct binding sites 
for Wnt proteins and BMPs (Piccolo et al., 1999). Finally, USAG-1 might also have dual 
activities, and play as a molecular link between Wnt and BMP signaling pathway (Yanagita 
et al., 2004). 
2.3.6 Skeletal phenotypes associated to Wnt signalling members 
Over 70 mendelian syndromes presenting with skeletal abnormalities in humans are 
associated to mutations in Wnt signaling-related genes. This large group include complex 
developmental disorders with multi-system implication due to severe imbalance of body 
patterning in embryo. Besides very rare and incompletely characterized syndromes, some of 
the most significant WNT-associated skeletal phenotypes are summarized in table 2. 
Overall, these diversified phenotypes are characterized alternatively by limb malformations 
and defective/eccessive ossification. 
Refer to the OMIM database (www.omim.org) for complete clinical information about the 
listed phenotypes and for additional Wnt-related genetic disorders. 
 
Genea Diseases MIMb 
LRP5 Hyperostosis, endosteal 
Osteopetrosis, autosomal dominant 1 
Osteoporosis-pseudoglioma syndrome 
Osteosclerosis 
van Buchem disease, type 2 
Bone mineral density variability 1 
144750 
607634 
259770 
144750 
607636 
601884 
WNT5A Robinow syndrome, autosomal 
dominant 
180700 
SOX9 Acampomelic campomelic dysplasia 
Campomelic dysplasia 
Campomelic dysplasia with autosomal 
sex reversal 
114290 
 
WNT10B Split-hand/foot malformation 6  225300 
WISP3 Arthropathy, progressive 
pseudorheumatoid, of childhood 
Spondyloepiphyseal dysplasia tarda with 
progressive arthropathy 
208230 
PRKAR1A Acrodysostosis with hormone resistance 101800 
FRZB Osteoarthritis susceptibility 1 165720 
ROR2 Brachydactyly, type B1 
Robinow syndrome 
113000 
268310 
a. gene symbol is provided; b. Mendelian Inheritance in Man (MIM) ID code. 
Table 2. Main mendelian syndromes associated to mutations in genes related to the Wnt-
signaling 
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2.4 Hedgehog homologs family 
Drosophila hedgehog (Hh) and its vertebrate orthologs, Sonic hedgehog (Shh), Indian 
hedgehog (Ihh), and Desert hedgehog (Ihh) are secreted proteins involved in the 
establishment cell fates at several points during development. The vast majority of 
information on the Hh system derives from the studies performed in Drosophila. Hh 
production occurs through a well documented process of synthesis and post-translational 
processing leading to cholesterol-modification. This biochemical feature allows the Hh 
proteins to permeate the plasma membrane and form diffusible multimeric complexes. 
These represent represent the biologically active forms required for long-range signaling 
across different tissues in the developing embryo (Ehlen et al., 2006). Further transduction 
depends on the presence of the tramsmembrane protein dispatched-1 (Disp1), which is 
essential for driving long-range Hh signaling in flies and mice (Burke et al., 1999). Once they 
reach the target site of action, Hh molecules bind to the surface receptor Patched-1 (Ptch1) 
and induce the release and functional activation of the transmembrane protein smoothened 
(Smo). Smo activation on its turn induce downstream signaling, including the de-repression 
of the transcription factors belonging to the glioma-associated family of zinc finger 
oncogenes (Gli-1, -2 and -3; vertebrate orthologs of the Drososphila Cubitus interruptus), 
resulting in the activation of target gene expression (Cohen, 2003). Gli proteins are DNA-
binding transcription factors which localize in the cytoplasm and play important roles 
during embryogenesis (Lum & Beachy, 2004). This is also substantiated by the implication of 
human GLI genes in complex developmental disorders (see paragraph 2.4.2 and table 3). 
The signal transduction events downstream of Smo are best understood in Drosophila, 
while the complete sequence of molecular events involved in Hh signaling in vertebrate 
skeletogenesis is still unclear. A growing number of studies during the last decade have 
been trying to clarify this issue (Ehlen, 2006). New evidences are taking root in suggesting 
that vertebrate Hh signaling is related to the function of the primary cilium, a specialized 
cell surface projection intensively involved in intercellular signaling, which is essential for 
the correct coordination of organogenesis. In fact, some molecules involved in the Hh 
signalling cascade localize to the primary cilium (Corbit et al., 2005; Haycraft et al., 2005; 
Singla and Reiter, 2006). In addition, mutations in components of the intraflagellar transport 
machynery are able to indirectly disrupt Hh signaling and lead to a wide range of human 
disorders, comprising severe impairment of organ patterning in their phenotypes (van 
Reeuwijk et al., 2011). 
2.4.1 Hh in bone biology 
Hedgehog signaling coordinates a variety of embryo patterning processes through a series 
of inductive interactions (Ehlen et al., 2006). In particular, in vertebrates Shh and Ihh are 
essential regulators of skeletogenesis as they provide positional information and initiate or 
maintain cellular differentiation programs, regulating the formation of cartilage and bone. 
They basically regulate endochondral ossification, acting either as paracrine modulators on 
adjacent cells or over long distances, leading to the axial and appendicular skeleton 
patterning (Ehlen et al., 2006). Indian hedgehog (Ihh) can be regarded as the osteogenic HH, 
being a signaling molecule expressed predominantly in pre-hypertrophic chondrocytes 
where it plays a major role in endochondral bone formation. Ihh functions in the growth 
plate are mediated through the parathyroid hormone-related peptide (PTHrP) (Vortkanp et 
al., 1996). In the absence of Ihh, PTHrP mRNA is undetectable in fetal bones (Kronenberg, 
2006).  
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The parathyroid hormone-related peptide (PTHrP) also named PTH-like hormone 
(PTHLH), is a key regulator of endochondral bone formation synthesized by perichondrial 
cells and chondrocytes in growing bones. This hormone was originally discovered as a 
circulating peptide increased in the hypercalcemia occurring during malignancies (Suva et 
al., 1987). As a circulating hormone the PTHrP has pleiotropic functions, while during 
endochondral bone formation it acts in a juxtacrine/paracrine manner, binding to the same 
receptor as paratohomone (PTH/PTHrP Rec or PTHR1); the signal is transduced in the 
intracellular compartment via the recruitment of multiple G proteins and subsequent 
activation of adenylate cyclise, which generates cAMP. cAMP-dependent PKA then promote 
a downstream cascade leading to the suppression of target genes, including RunX2. PKA 
also phosphorylates and activate SOX9. The PTHR1 is expressed by chondrocytes as they 
stop proliferating. PTHrP then induces proliferation and delays chondrocyte hypertrophy 
(Kronenberg, 2006). Mice missing either the PTHrP or its receptor genes undergo a 
truncated endochondral sequence leading to shorter or absent column of proliferating 
chondrocytes in fetal bones and usually die shortly after birth, due to severe impairment of 
rib cage development (Amizuka et al., 1994; Chung et al., 1998). Conversely mice 
overexpressing either genes show bones with increased number of proliferating 
chondrocytes giving rise to delayed endochondral sequence (Weir et al., 1996). 
2.4.2 Skeletal phenotypes associated to HH family members 
Due to their essential role in embryo development, mutations of the HH family genes imply 
severe alteration of vertebrate body patterning and affect the cell proliferative homeostasis 
leading to tumorigenesis. There are at least three defined phenotypes that are directly 
ascribable to HH gene mutations in humans. Noticeably, being essential for the endochondral 
ossification throughout the developing skeleton, human IHH mutations in homozygosis lead 
to malformations involving both appendicular and axile skeletal structures (see table 3). Main 
mendalian disorders of the whole HH signaling are listed in table 3.  
 
Genea Diseases MIMb 
IHH Acrocapitofemoral dysplasia 
Brachydactyly, type A1 
607778 
112500 
SHH Single median maxillary central incisor 147250 
PTHLH Brachydactyly, type E2 613382 
GLI3 Greig cephalopolysyndactyly syndrome 
Pallister-Hall syndrome 
Polydactyly, postaxial, types A1 and B 
Polydactyly, preaxial, type IV 
175700 
146510 
174200 
174700 
a. gene symbol is provided; b. Mendelian Inheritance in Man (MIM) ID code. 
Table 3. Selected mendealian malformation syndromes of HH signaling molecules 
2.5 The FGF/FGFR signaling 
Fibroblast growth factors (FGFs) and corresponding receptors (FGFRs) are known to play 
important roles during bone development. FGF signaling is essential for maintaining bone 
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homeostasis and during fracture healing. The FGF family currently comprises over 20 
structurally related members that bind to tyrosine kinase transmembrane receptors. Upon 
binding FGFR on its extracellular ligand-binding domain, FGF causes the dimerization of 
receptor monomers, leading to autophosphorylation of tyrosine residues on the intracellular 
signal transduction domain (Su et al., 2008). Alternative downstream signal transduction 
pathways have been described that basically imply the activation of the mitogen-activated 
protein kinase (MAPK) signaling. (Eswarakumar et al., 2005). 
2.5.1 FGFs/FGFRs in bone biology 
FGF sigaling is crucial in both endochondral and intramembranous ossification. Different 
FGF ligands are expressed in the mesenchyme of the limb bud at the stage of condensation 
and later in chondrocytes and osteoblasts in the growth plate of developing long bones 
(Colvin et al., 1999; Lazarus et al., 2007; Yu et al., 2003). During the cyclic 
proliferation/hypertrophy stages of endochondral bone formation, more then ten different 
FGF molecules are expressed in a perfectly spatio-temporal coordinated fahion (Lazarus et 
al., 2007). Particularly, converging evidences indicate FGF2 as the earliest marker gene to be 
expressed in prechondrocyte condensation stages, while FGF1 and FGF3 appear later in 
differentiated chondrocytes (Lazarus et al., 2007; Yu et al., 2003). 
Lessons from genetically modified mouse models and in vitro studies indicated that 
excessive Fgf2 inhibits chondrogenesis, resulting in decreased bone elongation, 
hypertrophic diffentiation and abnormal chondrocyte proliferation (Montero et al., 2000; 
Sobue et al., 2005). Conversely, mice lacking Fgf2 display reduced bone formation and 
abnormal bone structure (Montero et al., 2000). Overall, the correct dosage of Fgf2 is 
essential for the bone growth and homeostasis (Su et al., 2008). Similarly, other FGF ligands 
have a documented role in limb outgrowth and patterning, from the stage of condensation 
till osteoblastic differentiation, indicating some kind of redundancy among FGF signaling 
(de Lapeyriere et al., 1993; Fiore et al. , 1997; Finch et al., 1995; Guo et al., 1996; Haub et al., 
1991; Hebert et al., 1994). 
With regard to intramembranous ossification, all Fgfs, except Fgf-3 and -4, are expressed in 
coronal suture in the mouse embryo and in other mesenchymal sutures during craniofacial 
development (Su et al., 2008). The role of FGF/FGFR signaling in promoting 
intramembranous ossification is indeed strongly supported by the association of FGFR1-3 
genes in human craniosynostosis syndromes (see table 4). Increased FGF signaling cause 
increased proliferation rates in suture-derived calvarial cells leading to premature suture 
closure (i.e. synostosis; H.J. Kim et al., 1998). FGF signaling also regulates calvarial cell 
differentiation. Therefore, FGF signaling exerts a dual effect on osteoblast biology, inducing 
proliferation of immature osteoblasts and apoptosis in differentiated osteoblasts 
(Mansukhani et al., 2000). The pro-differentiation effects should be the result of Runx2-
induced expression of osteocalcin, enhanced by Fgf2 (H.J. Kim et al., 2003). FGF signaling 
actually cross-talks with the other osteogenic pathways, including Msx2, Twist, Bmp and 
other TGF-β superfamily members, during calvarial suture morphogenesis (Opperman, 
2000; Rice at al, 2005). 
2.5.2 Skeletal phenotypes associated to FGF signaling; The FGFR syndromes 
Missense mutations in either FGFs or FGFRs human genes cause a variety of congenital 
skeletal disorders, including syndromic craniosynostosis (CRS) and hypo/achondroplasia, 
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among others (extensively reviewed by Su et al., 2008). In particular, both CRS syndromes 
and chondrodysplasias, are associated to gain-of-function mutations in either of the FGFR-1, 
-2 and -3 genes, which imply the constitutive activation of the kinase receptor activity 
regardless of ligand binding on the extracellular domain. A list of the best characterized 
malformation syndromes associated to FGFR gene mutations (the autosomal dominant 
“FGFR syndromes”) is provided in table 4, as paradigmatic examples of the effects of FGF 
signaling impairment in human diseases. The functional relevance of the most common 
FGFR gene mutations of syndromic craniosynostosis has been further examined using 
animal models and in vitro studies (Su et al., 2008). 
 
Genea Diseases MIMb 
FGFR2 Antley-Bixler syndrome
Apert syndrome  
Beare-Stevenson cutis gyrata syndrome 
Crouzon syndrome 
Gastric cancer, somatic 
Jackson-Weiss syndrome 
LADD syndrome 
Pfeiffer syndrome 
Saethre-Chotzen syndrome 
Scaphocephaly with maxillary retrusion and mental retardation
207410 
101200 
123790 
123500 
137215 
123150 
149730 
101600 
101400 
609579 
FGFR3 Achondroplasia
CATSHL syndrome 
Crouzon syndrome with acanthosis nigricans 
Hypochondroplasia 
LADD syndrome 
Muenke syndrome 
Thanatophoric dysplasia, type I 
Thanatophoric dysplasia, type II 
100800 
610474 
612247 
146000 
149730 
602849 
187600 
187601 
FGFR1 Jackson-Weiss syndrome
Osteoglophonic dysplasia 
Pfeiffer syndrome 
Trigonocephaly 
123150 
166250 
101600 
190440 
Table 4. The FGFRs syndromes: skeletal malformations associated to FGFRs: a. gene symbol 
is provided; b. Mendelian Inheritance in Man (MIM) ID code. 
2.6 TWIST 
The Twist homolog 1 (Drosophila), TWIST1, belongs to the basic helix-loop-helix (bHLH) 
class of transcriptional regulators that dimerize to form a bipartite DNA binding groove, 
which recognize a consensus DNA element and alter the chromatin structure (Pan et al., 
2009). Twist1 represents a critical modulator of mesenchymal cell fate during skeletal 
development, inducing differentiation toward both the chondrogenic and the osteogenic 
lineages, while inhibiting myogenesis (Miraoui & Marie, 2010). In Drosophila, twist 
homozygous mutations are associated to a lethal phenotype, due to disruption of 
gastrulation and failure in mesodermal-derived organ development and leading to complete 
eversion of head; the embryo was twisted in the egg, hence the name given to the gene 
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(Simpson, 1983). Heterozygous mutations in the Twist1 gene usually determine loss-of-
function due to haploinsufficiency (Zackai and Stolle, 1998). In fact, mice heterozygous for a 
Twist null mutation exhibited cranial and limb defects (Bourgeois et al.. 1998; El Ghouzzi et 
al.. 1997). Such findings, allowed to confirm TWIST1 as the candidate gene for the Saethre-
Chotzen syndrome (MIM#101400, autosomal dominant), characterized by craniofacial and 
limb malformations and indicated a key role of TWIST in n the mesodermal development of 
the head and limbs (El Ghouzzi et al., 1997; Gripp et al., 2000; see following sections). 
Thereafter, Twist role in calvarial bone/suture patterning and development has been 
intensively investigated (Miraoui & Marie, 2010). In this context. Twist1 appears to act as an 
upstream transcriptional regulator of FGFRs (Shishido et al., 1993). 
2.7 The RANK/RANKL/OPG system in bone biology 
Bone resorption, required during endochondral bone formation and bone remodeling, is 
driven by functional activation of osteoclasts. It is now clear that the complete maturation of 
osteoclasts occurs only in presence of osteoblasts (Grano et al., 1990; Teti et al, 1991). The 
molecular basis of this fundamental interaction resides in the interplay between the receptor 
activator of nuclear factor kappa B (RANK), its ligand (RANKL) and the osteoprotegerin 
(OPG). 
RANK is a homotrimeric transmembrane receptor, belonging to the tumor necrosis factor 
(TNF) receptor superfamily, expressed on the cell surface of osteoclast precursors and 
mature osteoclasts. RANKL, also called OPG-ligand or osteoclast differentiation factor 
(ODF), also belong to the TNF superfamily and is expressed in osteoblasts (Boyce and Xing, 
2008). The interaction between RANK and RANKL induces a downstream signalling, that 
involves the nuclear factor kB (NFKB), with subsequent transcriptional activation of target 
genes leading to recruitment, differentiation, activation and survival of osteoclasts. 
OPG, also known as tumor necrosis factor receptor superfamily member 11 (TNFRSF11) or 
osteoclastogenesis inhibitory factor (OCIF) is a soluble receptor of RANK, exrpressed in 
osteoblasts, stromal cells and other non-skeletal cells. OPG acts as a decoy receptor for 
RANKL, as it prevents RANK/RANKL interaction and inhibits osteoclastogenesis and bone 
resorption (Khosla, 2001). The RANKL/OPG ratio represents a major determinant in bone 
mass regulation, as inferred from the OPG-deficient mouse, which displays an osteoporotic 
phenotype with increased osteoclasts (Bucay et al., 1998). Conversely, OPG overexpression 
leads to osteopetrosis (Simonet et al., 1997). 
OPG expression is regulated by the canonical Wnt pathway, which regulates osteoclasts by 
increasing the OPG/RANKL ratio (Suzuki et al., 2008). The OPG/RANKL ratio in 
osteoblasts is also regulated by bone remodeling hormones. Both parathormone (PTH) and 
vitamin D decrease the ratio by the transcriptional up-regualtion of RANKL. Conversely, 
estrogens increase OPG production in osteoblasts, hence increase bone formation and 
reduce resorption (Zallone, 2006). More recently a role in the control of bone remodeling has 
been emerging for leptins, serotonin and insulin, probably acting through the RANKL/OPG 
system (Elefteriou, 2005; Huang et al, 2009). 
2.7.1 Skeletal phenotypes associated to OPG mutations 
Besides the documented involvement of the RANK/RANKL/OPG system in the 
pathogenesis of acquired multifactorial bone remodeling disorders, such as osteoporosis 
and osteoarthritis, OPG is also emerged as a genetic disease-associated gene. 
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Homozygous or compound heterozygous mutations of TNFRSF11 have been found in 
juvenile Paget disease of bone (MIM#239000), characterized by systemic hyperhostosis, 
with typically increased skull bone thickness, hyperphosphatemia and progressive 
skeletal deformities. 
2.8 Notch signaling 
Evolutionarily conserved Notch signaling plays an important role in developmental 
processes and adult tissue homeostasis by regulating cell fate determination, proliferation, 
differentiation and apoptosis in a spatio-temporal coordinated manner. The Notch receptor 
and its ligands are transmembrane proteins whose signaling requires cell to cell contact 
between neighboring cells (Engin & Lee, 2010). Four Notch receptors (Notch1-4) are known 
in mammals, while Notch ligands fall into two classes: Delta and Jagged. Subsequent 
cleavage steps occur upon Notch receptor/ligand interaction to activate the Notch 
intracellular domain (Notch ICD) that is then released from the membrane, and translocated 
to the nucleus (Hayes et al, 2003). In the nucleus, Notch ICD binds specific transcription 
factors and recruits transcriptional co-activators to induce the expression of a basic helix- 
loop-helix (bHLH) family of genes (Engin & Lee, 2010). 
Notch signaling is involved in skeletal patterning and somitogenesis, as related molecules 
are expressed in the presomitic mesoderm (PSM) of mouse embryos. Notch1 null mouse 
embryos exhibits significantly delayed and disorganized somitogenesis (Conlon et al., 1995; 
Turnpenny et al., 2007). 
Converging evidences suggest that Notch pathway is active in the early stages of osteoblast 
differentiation, also by acting on Runx2-dependent osteogenic gene expression (McLarren et 
al., 2000; Tezuka et al., 2002). Nonetheless, this issue is currently debated. Notch could also 
regulate osteoclastogenesis, through the up-regulation of RANKL and OPG genes, 
suggesting that the functional cross-talk between osteoblasts and osteoclasts might be also 
mediated by Notch signaling (Engin & Lee, 2010). Finally, Notch signaling is believed to act 
also in chondrogenic differentiation, although its exact role and its temporal effects during 
chondro/osteoblastogenesis are still unclear. 
Getting into the clinical field, mutations in Notch pathway genes are the etiology of two 
genetic disorders with severe skeletal impairment: Spondylocostal dysostosis type 1 
(SCDO1, MIM#602768) and Alagille syndrome (AGS, MIM#118450), both characterized by 
vertebral column defects (Bulman et al., 2000; L. Li et al., 1997). This clinical evidence, 
confirm the best characterized function of NOTCH signaling as a regulator of somitogenesis. 
2.9 Homeobox genes 
The homeobox genes belonging to the muscle segment homeobox gene (Msx) family, Msx-1 
and Msx-2, are implicated in the regulation of craniofacial skeletal morphogenesis (AÏoub et 
al., 2007; Berdal et al., 2009; Orestes-Cardoso et al., 2002). Msx genes are expressed in the 
cranial neural crest (CNC) cells where they regulate migration and proliferation and specify 
tissue lineage differentiation fates. They preferentially support skeletal tissue development 
and they contribute extensively to the formation of the craniofacial skeleton (Bendall & 
Abate-Shen, 2000). Msx1 and Msx2 genes are expressed in osteoclasts and drive the 
membranous ossification. In particular, Msx1 has been functionally associated with 
mandible development, while Msx2 as been implicated in tooth eruption and elongation 
(AÏoub et al., 2007; Orestes-Cardoso et al., 2002). 
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The MSX homeoproteins are co-expressed with the distal-less homeobox gene (DLX) family 
in CNC cells and in various developing tissues. MSX and DLX molecules structurally and 
functionally interact in vitro by forming heterodimers via their homeodomains and 
reciprocally inhibit each other’s activities (Bendall & Abate-Shen, 2000). These homeoprotein 
families are jointly implicated in the control of craniofacial, axial, and appendicular skeletal 
morphogenesis (Alappat et al., 2003; Kraus and Lufkin, 2006; Lallemand et al.., 2005). In 
osteoblast differentiation, Msx activity counteracts the osteogenic-inducing property of Dlx 
during osteoblast differentiation. In mouse, Msx2 was found indeed to repress the 
expression of osteocalcin (OC), while Dlx genes were recruited to initiate OC transcription 
via RunX2 , leading to the final mineralization stage of osteoblast differentiation (Hassan et 
al., 2004). Thus, functional antagonism through heterodimer formation may provide a 
mechanism for regulating the transcriptional actions of Msx and Dlx in vivo. They were also 
shown to regulate one another’s expression , and to share target genes such as amelogenin 
(Alappat et al., 2003; Kraus and Lufkin, 2006). On the other hand, it has also been suggested 
that Msx and Dlx genes act independently in regulating the development of craniofacial 
skeleton (Levi et al., 2006). 
2.9.1 Skeletal disorders associated to MSX2 
The human homolog of Msx-2 (MSX2, MIM*123101), originally cloned in 1993 (X. Li et al., 
1993), has been associated to three distinct phenotypes, inherited as autosomal dominant 
tracts and sharing distinctive clinical features, such as craniofacial deformities of variable 
degrees, no limb involvement, and neurological symptoms (mainly represented by 
headache and seizures) among others (see www.ncbi.nlm.nih.gov/omim for detailed 
descriptions). A proline-to-hystidine substitution in the homeodomain of MSX2 was 
found in the Boston-type Craniosynostosis syndrome (type 2 Craniosynostosis, 
MIM#604757), a skeletal developmental disorder characterized by skull malformations 
(from mild asymmetry to trilobular skull with craniosynostosis, the so-called cloverleaf 
skull) and neurological symptoms usually without mental retardation (Muller et al., 1993; 
Warman et al., 1993). Deletion of the entire gene or mutations affecting the DNA-binding 
affinity of MSX2 where found in kindreds affected by the parietal foramina type 1 
syndrome (PFM1; MIM#168500), featured by symmetric calvarial defects in the parietal 
bone, variably associated with additional craniofacial malformations (including cleft 
lip/palate, scalp defects and cranium bifidum), headache and seizures. Finally, parietal 
foramina with cleidocranial dysplasia (PFMCCD, MIM#168550) has been recently 
classified as a distinct MSX2-related mendelian disorder, in which the PFM phenotype is 
associated with clavicular hypoplasia and mild craniofacial dysmorphisms . In this latter 
case, a frameshift mutation in the homeodomain leading to premature termination of 
MSX2 translation was found (Garcia-Minaur et al., 2003). The association of these three 
allelic genetic diseases, strengthened the idea of MSX2 involvement in the control of 
membranous ossification. 
2.10 MicroRNAs 
The fine regulation of gene function necessary for the correct orchestration of osteogenesis 
and skeletal development may occur at several levels. One mechanism possibly acting in 
this process is represented by the post-transcriptional modulation operated by micro 
ribonucleic acids (microRNA or miRNA). miRNAs are a growing group of small (22 
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ribonucleotides), single-stranded, noncoding RNAs that generally attenuate gene function. 
They regulate the translation of specific messenger RNA (mRNA) by base pairing with 
target complementary sequences (Carthew & Sontheimer, 2009). miRNA were first 
discovered in the nematode Caenorhabditis elegans and then found in diverse species, 
showing high degrees of evolutionary conservation. MicroRNAs are involved in many 
developmental signaling pathways and in housekeeping regulation of organ physiology 
(Schramke & Allshire, 2003). Over 1400 human miRNAs are deposited in the widest miRNA 
database (Griffiths-Jones et al, 2004, 2006, 2008; Kozomara et al., 2011; 
http://www.mirbase.org/). With regard to the regulation of bone formation, a growing 
number of miRNAs are found to be expressed in the developing skeletal system of 
metazoan, where are reasonably involved in regulating skeletal tissue homeostasis and 
development (He et al, 2009). Besides the emerging role of miRNAs during embryo 
skeletogenesis, miRNA-dependent modulation of gene function can alter skeletal 
phenotypes across individuals and also within same individual over time. This 
interpretation derives from recent studies focusing on miRNA biology in the pathogenesis 
of osteoporosis. Different miRNAs are upregulated in sencescent mesenchymal cells, 
leading to reduced cell plasticity and multilineage potential. Being able to modify the cell 
differentiation fate, miRNAs should interfere with the main developmental signaling 
pathways. Particularly, recent evidences suggest that miRNAs might have a regulatory 
function in osteoblast differentiation (Z. Li et al, 2008). BMP signaling pathway can be 
modulated at various level by miRNA; relevant results that recently emerged on this issue 
are shortly cited as examples. Mir125b inhibits osteoblast differentiation by reducing the cell 
proliferation rate; miR26a has been shown to inhibit the osteogenic differentiation of 
adipose tissue-derived stromal cells through intereference on Smad1 translation ; on their 
turn, Smads participate in miRNA biogenesis (Mizuno et al, 2008); miR-2861 enhances 
BMP2-induced osteoblastogenesis by repressing the histone deacetylase 5 gene, which 
induce Runx2 degradation (H. Li et al, 2009). Another miRNA, namely miR-138, regulates 
the osteogenic differentiation of human mesenchymal stem cells in vivo (Eskildsen et al, 
2011). In addition, during BMP2-induced osteogenic differentiation of mesenchymal cells, 
the expression of miRNAs that target osteogenic genes is decreased (Z. Li et al, 2008). 
Hence, the pathogenic increase or decrease of miRNAs targeting osteogenic genes, along 
with the action of BMPs on miRNA biogenesis, may influence bone develoment, concurring 
in the pathogenesis of bone-defective or hyper-ossification disorders. 
Interestingly, several miRNA-coding genes are located within HOX gene clusters on 
evolutionary conserved chromosomal loci, and share their expression pattern. How this 
genomic situation could imply a HOX-miRNA functional interaction is still unclear, 
although Hox genes figure among miRNA targets (Yekta et al, 2008). 
Finally, distinct studies have demonstrated that sequence variations occurring in miRNA 
genes can be associated to human diseases or disease-predisposition (Calin et al, 2005; Duan 
et al, 2007; Jazdzewsky et al, 2008). A homozygous mutation in miR-2861 results in reduced 
osteoblast activity leading to osteoporosis (H. Li et al, 2009). The evolution of craniofacial 
variation among species, the development of human craniofacial disease, and the 
physiological changes leading to osteopenia/osteoporosis that increases with aging, could 
result from evolutionary variation in miRNA expression patterns and/or structural 
modifications in miRNA binding sites in mRNAs, thus depicting a brand new era in the 
genetics of human diseases (He et al, 2009). 
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3. Conclusion 
Overall, the molecular scenario that has been systematically described in this chapter could 
allow understanding the complexity of bone tissue homeostasis. Far from being considered 
a “resting” differentiated tissue, bone appears to be extremely plastic, as the control of its 
homeostasis is driven by thousand of genes interacting in complex developmental networks, 
along with post-translational and epigenetic mechanisms that can modify the genome 
performance. 
The number of actors playing in this scene is much wider than that described here, thus the 
screenplay of osteogenesis is still too complex to allow depicting an exhaustive overview. 
This complexity implies an extremely high number of human diseases affecting bone 
development, formation and integrity, that possibly can grow over as the genetic body of 
knowledge further develops. 
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